[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphatic-obstruction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphatic-obstruction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100642449","early-phase-1-18f-ftha-imaging-of-the-intestinal-and-central-lymphatic-system-100642449",false,"NCT07645573","18F-FTHA IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEM","INVESTIGATION OF A POSITRON-EMITTING LONG-CHAIN FATTY ACID (18F-FTHA), FOR IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEM","FTHA","Inclusion Criteria:\n\nInclusion Criteria (Healthy Volunteer Cohort)\n\n1. Male and female participants will be ≥ 18 years of age.\n2. \"Healthy Volunteer\" is defined for the purposes of this study as a volunteer who is in good general health in the opinion of an investigator (some well controlled chronic medical conditions may be allowed at the discretion of an investigator if they do not believe they will interfere with the collection of imaging data, specific excluded medical conditions are listed under exclusion criteria).\n3. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nInclusion (Patient with suspected TD-venous junction obstruction cohort)\n\n1. Male and female participants will be ≥ 18 years of age\n2. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n3. Patient with chronic abdominal pain, ascites protein losing enteropathy, as well edema, with clinically suspected obstruction of the TD-venous junction and who are candidates for TD-venous junction plasty and or TD-Venous bypass\n\nExclusion Criteria:\n\nExclusion Criteria that apply to Healthy Volunteers only\n\n1. Currently taking medication for cardiac disease, hypertension, hyperlipidemia, diabetes mellitus, heart failure, coronary artery disease, and\u002For history of cardiac surgery per medical record review and\u002For self-report\n2. Known history of liver or kidney disease per medical record review and\u002For self-report\n\nExclusion Criteria that applies to Healthy Volunteers and Patients:\n\n1. Women who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential on the day of each of the PET\u002FCT scans.\n2. Subjects who report claustrophobia or Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n3. Self-reported difficulty with swallowing pills or allergy to components of Ensure Plus\n4. Patients with a history of medical illness or disorder that in the opinion of an investigator and\u002For study physician could compromise patient safety or interfere with the collection of imaging data, or ability to complete the study and procedures, will be excluded.\n\nParticipant may not be involved in any other research studies involving ionizing radiation conducted within 1 year of their participation of this study.",true,"ALL","18 Years",{"count":21,"type":22},25,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The project will be performed over a period of approximately two years. In the first year the \\[18F\\]FTHA tracer will be developed, optimized, and tested on normal volunteers. During the second year, the tracer will be investigated on patients with suspected obstruction of the thoracic duct (TD).",[28],"Lymphatic Obstruction",[30],"thoracic duct","RECRUITING","2026-06-08",{"date":34,"type":35},"2026-06-12","ACTUAL",{"date":37,"type":35},"2025-10-10",{"date":39,"type":22},"2029-06-30",{"name":41,"class":42},"University of Pennsylvania","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":5},"100606642","robotic-enabled-microsurgical-intervention-for-neurodegenerative-disease-100606642","NCT07178210","Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease","Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - A Global, Prospective, Early Feasibility Study in Alzheimer's Patients","REMIND","Inclusion Criteria:\n\n1. Patient aged 50 or older\n2. Patient has confirmed mild to moderate Alzheimer's Disease according to the National Institute of Aging-Alzheimer's Association (NIA-AA) criteria\n3. Patient has a positive amyloid PET test and\u002For a positive CSF t-tau\u002Famyloid-beta-42 test\n4. Patient has an MMSE score within the mild to moderate range (21-26 and 10-20)\n5. Patient has CDR-SB score within the mild to moderate range; mild is 4.5to 9.0 and moderate is 9.5 to 15.5\n6. Patient has confirmed extracranial lymphatic abnormalities in the head and neck region as identified by preoperative imaging\n7. Investigator deems the candidate acceptable for lymphatic surgery with a robotic-assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)\n8. Patient or their legally authorized representative agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure\n\nExclusion Criteria:\n\n1. Patient (or their legally authorized representative) is unwilling to provide informed consent\n2. Patient has suspected dementia of other type, e.g., Lewy body, frontotemporal disorder, vascular, etc.\n3. Patient has documented or suspected neurological or intracranial conditions such as cerebrovascular accident, tumors, intracranial space occupying lesions, seizures or other intracranial\u002Fneurological conditions that may affect their safety in the study.\n4. History of head and neck radiation exposure\n5. Patient with severe kidney disease (GFR \\\u003C30 mL\u002Fmin\u002F1.73m2)\n6. Patient with acute kidney injury\n7. Active systemic infection under treatment with intravenous antibiotics\n8. Patient has a modified Rankin Score (mRS) of \\>4\n9. Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigator's discretion\n10. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease\n11. Patient with an active cancer diagnosis and\u002For currently receiving treatment for cancer or has received treatment within the past 6 months\n12. Patient is currently receiving treatment or has been treated with anti-amyloid-beta monoclonal antibody therapy within the past 3 months\n13. Patient has contraindication for MRI or intrathecal administration of gadobutrol\n14. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or study outcomes\n15. Patient is ineligible to participate for other reasons in the judgment of the investigator","50 Years",{"count":54,"type":22},15,[56],"NA","The objective of this investigational device exemption (IDE) study is to evaluate the safety and feasibility of using the Symani System and microsurgical techniques in the deep cervical lymph node (dCLN) region in the setting of mild to moderate Alzheimer's disease and lymphatic abnormalities.",[59,28],"Alzheimer Disease","2026-06-01",{"date":62,"type":35},"2026-06-02",{"date":64,"type":35},"2026-04-30",{"date":66,"type":22},"2027-10-30",{"name":68,"class":69},"MMI (Medical Microinstruments, Inc.)","INDUSTRY"]